Fulgent Genetics Inc
$ 16.26
0.81%
17 Apr - close price
- Market Cap 507,810,000 USD
- Current Price $ 16.26
- High / Low $ 16.52 / 16.12
- Stock P/E N/A
- Book Value 35.78
- EPS -1.97
- Next Earning Report 2026-05-01
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.05 %
- ROE -0.06 %
- 52 Week High 31.04
- 52 Week Low 13.46
About
Fulgent Genetics, Inc., provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. The company is headquartered in Temple City, California.
Analyst Target Price
$24.33
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-07 | 2025-08-01 | 2025-05-01 | 2025-02-26 | 2024-11-08 | 2024-08-02 | 2024-05-03 | 2024-02-28 | 2023-11-03 | 2023-08-04 | 2023-05-05 |
| Reported EPS | 0.16 | 0.14 | -0.62 | 0.04 | 0.04 | 0.31 | 0.15 | -0.01 | 0.28 | -0.39 | -0.08 | -0.22 |
| Estimated EPS | -0.0602 | -0.22 | -0.18 | -0.1794 | -0.369 | -0.15 | -0.3 | -0.32 | -0.29 | -0.33 | -0.33 | -0.43 |
| Surprise | 0.2202 | 0.36 | -0.44 | 0.2194 | 0.409 | 0.46 | 0.45 | 0.31 | 0.57 | -0.06 | 0.25 | 0.21 |
| Surprise Percentage | 365.7807% | 163.6364% | -244.4444% | 122.2965% | 110.8401% | 306.6667% | 150% | 96.875% | 196.5517% | -18.1818% | 75.7576% | 48.8372% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-01 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.63 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: FLGT
2026-04-18 17:38:58
Lowey Dannenberg, P.C. is investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for potential violations of federal securities laws after the company reported full-year 2025 revenue that fell short of guidance and a sequential decline in fourth-quarter revenue. The firm is encouraging investors who suffered losses in Fulgent securities to contact them regarding the investigation.
2026-04-17 19:39:56
Lowey Dannenberg, P.C. is investigating Fulgent Genetics, Inc. (NASDAQ: FLGT) for potential violations of federal securities laws after the company reported disappointing financial results for the fourth quarter and full year 2025. Fulgent's full-year revenue of $322.7 million fell short of updated guidance, and fourth-quarter revenue declined sequentially. Investors who suffered losses in Fulgent securities are encouraged to contact the firm for more information.
2026-04-17 19:39:56
Lowey Dannenberg P.C. is investigating Fulgent Genetics for potential violations of federal securities laws, following the company's financial performance miss in Q4 and full-year 2025. The investigation stems from a reported sequential decline in fourth-quarter revenue and the company missing its updated guidance, which has impacted investor confidence and led to stock price volatility. Investors who suffered losses in Fulgent securities are being encouraged to seek legal remedies, potentially exposing the company to significant liabilities.
2026-04-17 05:39:48
Fulgent Genetics, Inc. (NASDAQ: FLGT) announced it will release its first quarter 2026 financial results before market open on Friday, May 1, 2026. The company will also host a conference call on the same day at 8:30 AM ET to discuss the results and answer questions from the investment community. Fulgent is a technology-based company with both laboratory services and therapeutic development businesses, aiming to transition into a fully integrated precision medicine company.
2026-04-16 11:38:51
Fulgent Genetics, Inc. (NASDAQ: FLGT) announced it will release its first quarter 2026 financial results before the market opens on Friday, May 1, 2026. The company will also host a conference call for investors on the same day at 8:30 AM ET to discuss the results and answer questions. Fulgent is a technology-based company with laboratory services and therapeutic development businesses.
2026-04-16 11:09:57
Fulgent Genetics, Inc. announced it will release its first-quarter 2026 financial results before market open on Friday, May 1, 2026. The company will host a conference call on the same day at 8:30 AM ET to discuss the results and answer questions. Fulgent is a technology-based company operating in laboratory services and therapeutic development, aiming to become a fully integrated precision medicine company.
